Gerd Zettlmeissl
Independent Chair of the BoardDr. Gerd Zettlmeissl, Ph.D, is an Independent Director of Valneva SE from June 25, 2025 and is its Chairman of the Board since June 25, 2026. Dr. Zettlmeissl served as Chairman of the Board at Minervax ApS since October 2021 until November 2024. He has been Independent Member of Supervisory Board at MediGene AG since May 04, 2017 and serves as its Chairman of the Supervisory Board since May 23, 2019. He served as Chief Executive Officer at Valneva USA, Inc. He was responsible for Business Development and Product Development at Intercell. He is experienced in developing and commercializing vaccines. He served as Member of Management Board at Intercell Ag from October 2001 to May 2011. He served as the Chief Executive Officer of Intercell Biomedical Research & Development AG (now known as Intercell Ag) from October 24, 2005 to May 10, 2011 and its Chairman of Management Board. He served as the Chief Executive Officer of Intercell in Austria until May 2011. He served as the Chief Operating Officer at Intercell AG from October 2001 to October 24, 2005. He was the international Head of Industrial and Quality Operations at Chiron Vaccines and Chief Executive Officer and Managing Director of Chiron Behring GmbH&Co – the fully integrated German subsidiary of one of the world’s largest biotechnology firms, Chiron Corporation. From 1994 to 1996, he was highly involved in the business’ merger with Chiron. He was Chairman of the Board at ASIT biotech s. a. since March 20, 2017 until December 17, 2018 and as its Independent Director since 2011 until December 17, 2018. He serves as the Chairman of Supervisory Board of Themis Bioscience GmbH. He serves as Chairman of Hilleman Laboratories. He served as the Chairman at GlycoVaxyn AG until 2015. He serves as Director of Aeras. He had been a Member of Scientific Advisory Board at CureVac N.V. since March 30, 2016 until September 2023 and joined since March 30, 2016. He serves as a Member of the Supervisory Board of the Helmholtz Zentrum für Infektionsforschung GmbH, a public research institute in Braunschweig, Germany. He served as a Director of Valneva USA, Inc. since 2008. He is the author of numerous scientific publications and is inventor/co-inventor of numerous patents in the field of biotechnology. He has been working in various R&D and General Management positions in the biopharmaceutical and vaccine industry since 1985. He joined Behringwerke AG (Marburg, Germany) in 1985 after conducting five years of academic research at the University of Regensburg and at the Institut Pasteur in Paris. His scientific background is in Molecular Biology and Protein Biochemistry. During his career, He made major contributions to the discovery, development and registration of a number of biologicals and vaccines. In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. He holds a Doctoral Degree in biochemistry of the University of Regensburg and post- doctoral fellowship at the Institut Pasteur Paris in virology from 1983 to 1985.
Positions
- Company NameValneva SEStock CodeVALNPositionIndependent Chair of the BoardColleagues
- TLThomas LingelbachPresident, CEO & Director
- PBPeter BuhlerChief Financial Officer
- JJJuan-Carlos JaramilloChief Medical Officer
- DPDipal PatelChief Commercial Officer
- VDVincent DequenneChief Operating Officer
- JRJames R. SulatIndependent Vice Chairman
- AGAnne-Marie GraffinVice-Chair of the Board
- RLRalf Leo ClemensChair of Scientific Advisory Board
